(B) Summary data for FS increased after 2 weeks of Fildena (SIL) treatment (n = 7-8 per group). The present study demonstrates that the PDE5 inhibitor Fildena ameliorates female cardiac pathologies caused by Gαq overexpression or pressure overload in an e

SAN FRANCISCO, CA—Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud's phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with Fildena improves endothelial function in men with increased cardiovascular risk. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic Fildena administration and improvement of endothelial function in men with erectile dysfunction: a pilot study.

Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of Fildena 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H, Wespes E, Cordell WH, Chan M, Lembo D. An evaluation of an alternative dosing regimen with Fildena, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Fildena prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study.

Jing ZC, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR, Wang Y, Yang YJ, Pu JL, Gao W. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Thiesson HC, Jensen BL, Jespersen B, Schaffalitzky de Muckadell OB, Bistrup C, Walter S, Ottosen PD, Veje A, Skøtt Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Evidence-based medicine with off-label use of PDE5 inhibitors is scarce but pilot studies suggest that chronic PDE5-i use determines better endothelial function and may slow down progression of atherosclerosis, especially in men with organic ED and endothelial dysfunction at baseline.

Thus, the hypothesis that Fildena may modulate aromatase activity in humans during acute and chronic administration highlights potential implications for the treatment of prostate and breast cancer. Overall, these data give the rationale for the chronic use of PDE5-i in men with ED and cardiovascular risk factors 33 Attention has been given to the endocrine effects of PDE5-i administration. The same group confirmed those results in men without ED and increased cardiovascular risk 31 Another possible explanation of increased endothelial function comes from pioneer studies suggesting a direct effect of PDE5-i on modulating the number of circulating endothelial progenitor cells (EPCs).

These benefits were confirmed by our group in a recent study in men with ED of broad etiology 30 In that study, it was demonstrated that the rehabilitative effects of chronic Fildena on vascular function occurs via improvement of surrogate markers of endothelial function, i.e. C-reactive protein, endothelin-1 and ICAM-1.


18.07.2018 01:02:12

Maecenas aliquet accumsan

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos hymenaeos. Etiam dictum tincidunt diam. Aliquam id dolor. Suspendisse sagittis ultrices augue. Maecenas fermentum, sem in pharetra pellentesque, velit turpis volutpat ante, in pharetra metus odio a lectus. Maecenas aliquet
Or visit this link or this one